The Patient Voice helps guide BioNTech design for UK Drug Trial

The UK Charity for Triple Negative Breast Cancer (TNBC) was recently able to ask it’s Patient Advisory Panel (PAP) members a series of important questions on behalf of the pharmaceutical company BioNTech. 

The answers provided critical information which will now be used by BioNTech to help inform the design of a trial for an investigational drug intended for people with the metastatic form of TNBC. 

A BioNTech spokesperson said ‘the results were extremely powerful’ and that they were ‘extremely grateful’ for those who took time to complete the questionnaire. 

This is particularly important as there are as yet relatively fewer treatment options for TNBC compared to other forms of breast cancer and will help inform the design of the trial.

The PAP has been set up by the Charity to enable patients lived experience of TNBC to be better understood and become the ‘Voice of TNBC’ to raise awareness and support. 

The PAP members have also contributed feedback to NICE on a recent treatment review, which they described as ‘invaluable’.